A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?

Shares of Omeros (NASDAQ: OMER) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.It was a deal with the Danish drugmaker that markets Ozempic and Wegovy that moved Omeros' stock price. Novo Nordisk (NYSE: NVO) will give the clinical-stage drugmaker $340 million upfront for exclusive global rights to develop and commercialize zaltenibart. This is the experimental complement system inhibitor formerly known as OMS906.As a company without any product sales, Omeros' deal with Novo Nordisk is significant. That said, there are no guarantees this chronic loss recording company will be able to make ends meet down the road. Here's a closer look at recent developments to see if it's a good stock to buy now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool